Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

The results of a Kruskal Wallis test comparing the various adherence metrics, during increasing and decreasing periods, by pandemic phase are shown as the title of each graph: The... حسب Barry Smyth (10826056)

IpaH9.8 mutants display decreased activity to degrade the GBPs. حسب Chenggong Ji (6858425)

Opinion distributions and mean shadow ban strength versus time under shadow banning control policies for different objective functions on a path network. حسب Yen-Shao Chen (18264587)

الموضوعات:

Fig 1 - حسب Gláucia Helena Fernandes Seixas (5866511)

A model for elucidating the transovarial transmission of <i>N</i>. <i>bombycis</i>. حسب Chunxia Wang (766713)

The nsP4-Q192L and C483Y mutations decrease the 4′-FlU sensitivity of both replication and transcription. حسب Peiqi Yin (6533747)

Decreased recovery times were observed after repeated handling and anesthesia sessions. حسب Lingzhi Wang (114519)

Opinion distributions and mean shadow ban strength versus time under shadow banning control policies for different objectives on a stochastic block model network. حسب Yen-Shao Chen (18264587)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Foldases and holdases each decrease the level of unfolded protein. حسب Adam MR de Graff (9767829)

Decreased UFA/SFA ratio induces cytosolic chaperones. حسب Dongyeop Lee (108880)

Mitochondrial fusion event (see Fig 7A). حسب Cynthia Alsayyah (18452506)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Video1_Case Report: Three-dimensional printed prosthesis reconstruction for patello-femoral large osteochondral defects in a patient with distal femoral giant cell tumour: A case r... حسب Dechao Yuan (12995895)

"…Although three-dimensional (3D)-printed prostheses are commonly adopted for tumour-induced bone defect reconstruction, patello-femoral osteochondral reconstruction with 3D-printed prostheses is rarely reported.</p><p>Case presentation: A 44-year-old female patient with progressive swelling and pain in the left knee for 6 months was diagnosed with Campanacci Grade II giant cell tumour (GCT). …"

Fzo1 is a natural PerMit tether in WT cells. حسب Cynthia Alsayyah (18452506)

الموضوعات:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. حسب Elizabeth S. Munroe (21568166)

الموضوعات: